Reply to "Letter to the editor of Annals of Surgical Oncology Concerning " The Landmark Series: Multimodality Therapy for Stage 3A Non-small Cell Lung Cancer" by Sunil Kumar et al. Ann Surg Oncol. 2021 06; 28(6):3433-3434.